Clinical trial
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic…
NCT00100711 · Pharmacyclics LLC., Industry · Terminated
Key facts
| NCT number | NCT00100711 |
|---|---|
| Title | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Official title | Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Refractory or Relapsed Disease |
| Lead sponsor | Pharmacyclics LLC., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma |
| Intervention type | Drug |
| Interventions | Motexafin Gadolinium |
| Enrollment | 27 |
| Start date | Oct 1, 2004 |
| Primary completion | Feb 1, 2010 |
| First posted | Jan 5, 2005 |
| Last update posted | May 23, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: